HERIZON-BTC-302
Tests whether the HER2 bispecific antibody should be given from the start in HER2-positive bile duct cancer.
Confirmatory trial for zanidatamab's accelerated approval (HERIZON-BTC-01: ORR 41%, OS 15.5 months; HER2 IHC 3+ ORR 52%, OS 18.1 months). Enrolling since 2024.
Setting
First-line HER2-positive advanced biliary tract cancer: zanidatamab + standard of care (GemCis ± PD-1) vs standard of care
Phase
Phase 3
Sponsor
Jazz / Zymeworks
Registry
Pages like this
not linked directly; found by shared links- TrialABC-02
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- CompanyZymeworks
Shares Zanidatamab, Biliary tract cancer (cholangiocarcinoma).
- TrialKEYNOTE-966
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TrialTOPAZ-1
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- PairingGemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TermIntrahepatic, perihilar, distal and gallbladder cancer
- PersonJeeyun Lee
Shares Zanidatamab, HER2.
- PersonDo-Youn Oh
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).